Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib plus SBRT in advanced HCC
NCT02906397Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galunisertib in hepatocellular carcinoma (HCC), sponsored by Abramson Cancer Center. Primary endpoint: Safety based upon standard laboratory and clinical adverse event monitoring. Started Mar 2017; status: completed.
02
Drugs
galunisertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02906397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906397.